Effect of desipramine on cerebrospinal fluid concentrations of corticotropin-releasing factor in human subjects.

Effect of desipramine on cerebrospinal fluid concentrations of corticotropin-releasing factor in human subjects. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Effect of desipramine on cerebrospinal fluid concentrations of corticotropin-releasing factor in human subjects. Abstract Text:

To assess the effect of desipramine (DMI) on corticotropin-releasing-factor (CRF) activity in the central nervous system, we measured cerebrospinal fluid (CSF) concentrations of CRF in healthy volunteers following short-term administration of DMI or placebo. DMI administration for 2 days was associated with a significant dose-related reduction in CRF concentrations. There was a nonsignificant 6% reduction in CRF concentrations among the 10 subjects who received 50 mg DMI (delta CRF: -3 +/- 2 pg/ml) and a significant 14% fall in the CRF concentrations of the eight subjects who received 100 mg DMI (delta CRF: -8 +/- 3 pg/ml). The mean CSF concentration of CRF was unchanged in the six subjects randomized to placebo (delta CRF: 1 +/- 5 pg/ml). DMI administration had no effect on CSF norepinephrine concentrations (n = 24) or on plasma cortisol (n = 25). We conclude that short-term administration of DMI in healthy volunteers is associated with a dose-related reduction in CSF concentrations of CRF.

Effect of desipramine on cerebrospinal fluid concentrations of corticotropin-releasing factor in human subjects. Publishing Authors By Initials

For similar endocrine system: endocrine glands: pituitary-adrenal system research abstracts see: endocrine system: endocrine glands: pituitary-adrenal system research

PUBMED ID PMID:

MEDLINE DATE:

Effect of desipramine on cerebrospinal fluid concentrations of corticotropin-releasing factor in human subjects. Journal Published:

PUBLICATION TYPE: Research Support, U.S. Gov't,

Journal: Psychiatry research

VOLUME: 46

Page Numbers: 1-8

Journal Abbreviation: Psychiatry Res

ISSN: 0165-1781

DAY: 17

MONTH: Jan

YEAR: 1993

Effect of desipramine on cerebrospinal fluid concentrations of corticotropin-releasing factor in human subjects. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 7911385

Effect of desipramine on cerebrospinal fluid concentrations of corticotropin-releasing factor in human subjects. Keywords Mesh Terms:

KEYWORDS: Pituitary-Adrenal System

MESH TERMS: drug effects

Chemical & Substance for Abstract: Effect of desipramine on cerebrospinal fluid concentrations of corticotropin-releasing factor in human subjects. Information

Substance Name: Corticotropin-Releasing Hormone

Registry Number: 9015-71-8

Grant and Affiliation Information for Effect of desipramine on cerebrospinal fluid concentrations of corticotropin-releasing factor in human subjects.

AFFILIATION: Geriatric Research, Education, and Clinical Center (GRECC), Department of Veterans Affairs Medical Center (DVAMC), Seattle, WA 98108.

Country: IRELAND

AGENCY: United States NIMH

GRANT: MH-42088

ACRONYM: MH

MEDLINETA: Psychiatry Res

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Effect of desipramine on cerebrospinal fluid concentrations of corticotropin-releasing factor in human subjects Related Publications

• An interactive web-based method of outreach to college students at risk for suicide.
• CSF corticotropin releasing hormone, somatostatin, and thyrotropin releasing hormone in schizophrenia.
• Cuba II: A Land Stuck in Time.
• Cuba: a land stuck in time.
• Decreased cerebrospinal fluid concentrations of substance P in treatment-resistant depression and lack of alteration after acute adjunct vagus nerve stimulation therapy.
• Depression and endocrine disorders: focus on the thyroid and adrenal system.
• Depression, desperation, and suicidal ideation in college students: results from the American Foundation for Suicide Prevention College Screening Project at Emory University.
• Drug development for anxiety disorders: new roles for atypical antipsychotics.
• Early-Life Adversity, CRF Dysregulation, and Vulnerability to Mood and Anxiety Disorders.
• Effect of desipramine on cerebrospinal fluid concentrations of corticotropin-releasing factor in human subjects.
• Emerging treatments for depression.
• Endogenous neurotensin is involved in estrous cycle related alterations in prepulse inhibition of the acoustic startle reflex in female rats.
• Fostering foster care outcomes: quality of intervention matters in overcoming early adversity.
• How are you?
• Involvement of neuropeptide systems in schizophrenia: human studies.
• Neuropeptides and Alzheimer's disease.
• Neurotensin: role in psychiatric and neurological diseases.
• New directions in the development of antidepressants: the interface of neurobiology and psychiatry.
• One brain, but different clinical disciplines: should psychiatry and neurology be United?
• Overview of the safety of citalopram.
• Sertraline and desmethylsertraline in human breast milk and nursing infants.
• Stress, menopause and vulnerability for psychiatric illness.
• The burden of severe depression: a review of diagnostic challenges and treatment alternatives.
• The dexamethasone/corticotropin-releasing factor test in men with major depression: role of childhood trauma.
• The interaction of serotonin transporter gene polymorphisms and early adverse life events on vulnerability for major depression.
• The neurobiology of bipolar disorder.
• The neurobiology of social anxiety disorder: the relevance of fear and anxiety.
• The pharmacokinetics of sertraline excretion into human breast milk: determinants of infant serum concentrations.
• The role of patient advocacy in funding policy.
• Understanding the pathophysiology of postpartum depression: implications for the development of novel treatments.